October 15, 2024 02:08 PM EDT
Pharma

J&J’s medtech slump con­tin­ues, im­prove­ments not ex­pect­ed un­til 2025

Max Bayer

Pharma Reporter

John­son & John­son beat in­vestors’ ex­pec­ta­tions de­spite its medtech unit un­der­per­form­ing, with ex­ecs point­ing to the Asia-Pa­cif­ic re­gion as a con­tin­ued source of strug­gle. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times